Sustained Viral Response (SVR) / Rapid Virologic Response (RVR) / Early Viral Response (EVR) / End of Treatment Response (EOT)
Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response - 4/21/09Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients - 4/21/09 A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy - 4/13/09Hepatitis C Virus May Persists at Low Levels after Sustained Response to Treatment; Liver Cancer May Develop Years Later - 2/06/2009 Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients - 2/03/2009 Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response - 1/30/2009 Sustained Virological Response Indicates Long-term HCV Eradication in People Successfully Treated for Chronic Hepatitis C - 10/14/08Higher Doses of Pegylated Interferon and Ribavirin May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis C - 10/10/08Sustained Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Does Not Always Prevent Hepatocellular Carcinoma - 10/10/08Genetic Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C Trial - 9/09/2008Rapid Viral Response and Sustained Treatment Outcome: A Comparison between 2 HCV RNA Assays - 8/05/2008Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR) - 8/05/200874 Percent of Genotype 1 HCV Patients in Experimental HCV PI Boceprevir Phase II Study Achieve Sustained Virologic Response (SVR) at 48 Weeks - 8/05/2008Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study - 7/22/08Adequate Ribavirin Exposure after the First Dose Predicts Sustained Virological Response to Hepatitis C Treatment in Genotype 1 Patients - 7/08/08HCV Genotype 1 Patients with High Viral Load Do Better with 48 vs 24 Weeks of Treatment, despite Rapid Virological Response - 7/04/08European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load - 7/04/08Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes - 6/24/08 Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes - 6/24/08 Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years - 5/30/08 Very Early Response to Interferon-based Therapy for Hepatitis C Is Apparent within the First 24 Hours - 5/30/08Duration of Pegylated Interferon plus Ribavirin May Be Tailored Based on Early Response - 1/04/08
FDA-approved
Combination Therapies for Chronic HCV Infection
